Sugi Predict

Sugi Predict / Compounds / SCHEMBL975049

SCHEMBL975049

SCHEMBL975049

Cc1ccccc1C[C@@H](N)CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 6/20 0.56
▸ DPP7 Q9UHL4 2/20 0.56
▸ DPP8 Q6V1X1 3/20 0.48
▸ DPP9 Q86TI2 3/20 0.48
▸ FAP Q12884 2/20 0.48
▸ PPARG P37231 1/20 0.44
▸ PPARA Q07869 1/20 0.44
▸ FFAR1 O14842 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CTBP2 P56545 1/20 0.42
▸ S1PR2 O95136 1/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ TAAR1 Q96RJ0 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ CPA1 P15085 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL975050 1.00 DPP4 (0.56) DPP4DPP7DPP8DPP9FAP
SCHEMBL29478407 1.00 DPP4 (0.56) DPP4DPP7DPP8DPP9FAP
SCHEMBL29478392 1.00 DPP4 (0.56) DPP4DPP7DPP8DPP9FAP
SCHEMBL2029955 1.00 DPP4 (0.56) DPP4DPP7DPP8DPP9FAP
SCHEMBL5580928 0.83 DPP4 (0.47) DPP4DPP7DPP8DPP9FAP
SCHEMBL27886746 0.83 S1PR2 (0.52) DPP4DPP7DPP8DPP9FAP
SCHEMBL5322923 0.83 S1PR2 (0.52) DPP4DPP7DPP8DPP9FAP
SCHEMBL3319873 0.82 DPP4 (0.52) DPP4DPP7DPP8DPP9FAP
Hydrochloric Acid SCHEMBL27886740 0.82 S1PR2 (0.51) DPP4DPP7DPP8DPP9FAP
SCHEMBL5320582 0.81 S1PR2 (0.50) DPP4DPP7FFAR1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 — — US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 — — US disclosed
EP-4578868-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
EP-4578867-A1 CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM CORPORATION (JP) 2025-06-05 — — US disclosed
US-20250179120-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM CORPORATION (JP) 2025-06-05 — — US disclosed
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF Synthorx, Inc. (US) 2025-03-13 — — US disclosed
US-12214043-B2 Therapeutic nanomaterials UNIVERSITY OF CONNECTICUT 2025-02-04 — — US disclosed
US-12173291-B2 Unnatural base pair compositions and methods of use THE SCRIPPS RESEARCH INSTITUTE (US) 2024-12-24 — — US disclosed
US-8343475-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-01 — — US disclosed
US-20120308587-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 — — US disclosed
EP-2456762-A1 DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS Theravance, Inc. (US) 2012-05-30 — — EP disclosed
US-20110236429-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-09-29 — — US disclosed
US-20110150917-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 — — US disclosed
US-20110021527-A1 DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS THERAVANCE BIOPHARMA R&D IP, LLC 2011-01-27 — — US disclosed
WO-2011011232-A1 DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS THERAVANCE, INC. (US) 2011-01-27 — — WO disclosed
EP-2061886-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES The University of British Columbia (CA) 2009-05-27 — — EP disclosed
WO-2008151434-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-12-18 — — WO disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT DPP4 1357/4885DPP7 865/4885DPP8 827/4885
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR MLX, BMX, ADM2 DPP4 1217/4885DPP7 481/4885DPP8 994/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 DPP4 1271/4885DPP7 1768/4885DPP8 1738/4885
US-20250179120-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR MDN1, MLX, BMX DPP4 1374/4885DPP7 453/4885DPP8 959/4885
US-12173291-B2 Unnatural base pair compositions and methods of use RNGTT, SPOUT1, NPEPPS DPP4 2157/4885DPP7 772/4885DPP8 726/4885
US-20120308587-A1 NEPRILYSIN INHIBITORS MME, REN, ACE DPP4 27/4885DPP7 34/4885DPP8 53/4885
US-20110021527-A1 DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS AGTR1, AGTR2, REN DPP4 54/4885DPP7 35/4885DPP8 84/4885
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF RNGTT, TRMT1, OSGEP DPP4 2835/4885DPP7 1615/4885DPP8 1277/4885
US-12214043-B2 Therapeutic nanomaterials TIE1, TEKT1, POLRMT DPP4 1357/4885DPP7 865/4885DPP8 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.